[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100417005":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":21,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":27,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":25,"sex":29,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":30,"phases":7,"briefSummary":31,"conditions":32,"keywords":36,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","REGN4461","To be provided by Regeneron",[14],"mibavademab",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Requests for Expanded Access must be initiated by a treating physician. Physicians should contact","CONTACT","844-734-6643","Managedaccessrequests@regeneron.com",{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100417005","expanded-access-to-regn4461-for-patients-with-diseases-associated-with-deficient-leptin-signaling-100417005",false,"NCT04710056","Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling","Key Inclusion: N\u002FA\n\nKey Exclusion: N\u002FA","ALL","EXPANDED_ACCESS","Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.",[33,34,35],"Lipodystrophy","Generalized Lipodystrophy (GLD)","Monogenic Obesity (MOB)",[37,38,39],"Leptin (LEP)","Leptin Receptors (LEPR)","Biallelic Loss of Function Variants of the LEP Gene","AVAILABLE","2026-03-10",{"date":43,"type":44},"2026-03-12","ACTUAL",{"name":5,"class":6}]